Joy M. Greer

575 total citations
8 papers, 403 citations indexed

About

Joy M. Greer is a scholar working on Genetics, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Joy M. Greer has authored 8 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Genetics, 3 papers in Oncology and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Joy M. Greer's work include Chronic Lymphocytic Leukemia Research (4 papers), Advanced Breast Cancer Therapies (2 papers) and Spondyloarthritis Studies and Treatments (2 papers). Joy M. Greer is often cited by papers focused on Chronic Lymphocytic Leukemia Research (4 papers), Advanced Breast Cancer Therapies (2 papers) and Spondyloarthritis Studies and Treatments (2 papers). Joy M. Greer collaborates with scholars based in United States, Germany and Belgium. Joy M. Greer's co-authors include Luc Meuleners, R. Besuyen, Neelufar Mozaffarian, Chantal Tasset, Walid Abi‐Saab, Thijs Hendrikx, Ke Liu, Oleg Nadashkevich, Xenofon Baraliakos and Atul Deodhar and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Joy M. Greer

8 papers receiving 398 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joy M. Greer United States	4	284	199	155	110	45	8	403
Luc Meuleners Belgium	7	414 1.5×	239 1.2×	221 1.4×	152 1.4×	39 0.9×	22	562
Iris C. Blijdorp Netherlands	11	242 0.9×	284 1.4×	140 0.9×	28 0.3×	66 1.5×	18	399
Horny Hp Germany	12	224 0.8×	316 1.6×	88 0.6×	41 0.4×	75 1.7×	23	434
Amir Kadi France	9	133 0.5×	119 0.6×	70 0.5×	55 0.5×	76 1.7×	11	275
A. E. Irvine United Kingdom	8	116 0.4×	202 1.0×	83 0.5×	82 0.7×	144 3.2×	9	417
Chantal L. Duurland Netherlands	8	62 0.2×	253 1.3×	75 0.5×	99 0.9×	68 1.5×	11	385
Laura Wisch United States	6	38 0.1×	214 1.1×	133 0.9×	69 0.6×	50 1.1×	10	336
JR Kalden Germany	9	68 0.2×	226 1.1×	70 0.5×	72 0.7×	94 2.1×	15	407
Carelle C. Reparon‐Schuijt Netherlands	7	206 0.7×	131 0.7×	34 0.2×	42 0.4×	33 0.7×	9	337
Anne Myerscough United Kingdom	8	177 0.6×	171 0.9×	23 0.1×	64 0.6×	59 1.3×	11	346

Countries citing papers authored by Joy M. Greer

Since Specialization

Citations

This map shows the geographic impact of Joy M. Greer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joy M. Greer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joy M. Greer more than expected).

Fields of papers citing papers by Joy M. Greer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joy M. Greer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joy M. Greer. The network helps show where Joy M. Greer may publish in the future.

Co-authorship network of co-authors of Joy M. Greer

This figure shows the co-authorship network connecting the top 25 collaborators of Joy M. Greer. A scholar is included among the top collaborators of Joy M. Greer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joy M. Greer. Joy M. Greer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Diamond, Jennifer R., Valentina Boni, Emerson A. Lim, et al.. (2022). First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. Clinical Cancer Research. 28(7). 1285–1293. 30 indexed citations

Frigault, Melanie M., Hermes Garbán, Joy M. Greer, et al.. (2022). Abstract 1859: VIP152, a selective CDK9 inhibitor, demonstrates sensitivity in gynecologic cell lines that are cisplatin sensitive or resistant and delivers in vivo antitumor efficacy. Cancer Research. 82(12_Supplement). 1859–1859. 1 indexed citations

Beaver, Larry, Katie Williams, Shelley Orwick, et al.. (2021). VIP152 Is a Novel CDK9 Inhibitor with Efficacy in Chronic Lymphocytic Leukemia. Blood. 138(Supplement 1). 270–270. 2 indexed citations

Frigault, Melanie M., Harvey Wong, Hermes Garbán, et al.. (2021). VIP152, a Selective CDK9 Inhibitor, Induces Complete Regression in a High-Grade B-Cell Lymphoma (HGBL) Model and Depletion of Short-Lived Oncogenic Driver Transcripts, MYC and MCL1, with a Once Weekly Schedule. Blood. 138(Supplement 1). 1192–1192. 2 indexed citations

Besuyen, R., Arthur Kavanaugh, René Westhovens, et al.. (2020). P525 Rheumatoid arthritis treatment with filgotinib: Week 156 safety and efficacy data from a phase 2b open-label extension study. Journal of Crohn s and Colitis. 14(Supplement_1). S452–S452. 3 indexed citations

Heijde, Désirée van der, Xenofon Baraliakos, Lianne S. Gensler, et al.. (2018). Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. The Lancet. 392(10162). 2378–2387. 194 indexed citations

Mease, Philip J., Laura C. Coates, Philip Helliwell, et al.. (2018). Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. The Lancet. 392(10162). 2367–2377. 156 indexed citations

Overman, Michael J., Charles D. Lopez, Al B. Benson, et al.. (2016). A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology. 34(15_suppl). 4130–4130. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact